Motus Nova announced today that it is expanding its list of partner hospitals and clinics using the device, as well as making plans to introduce its patented system to the consumer market for home use in Q3 2019.
Twenty-five hospitals in the Atlanta area within Emory Healthcare, the Grady Health System and the Wellstar Health System are joining the growing list of hospitals that have partnered with Motus Nova to use its technology for rehabilitation therapy for stroke survivors.
A collaborator with top-ranked institutions such as Mayo Clinic, Cleveland Clinic and Massachusetts General Hospital, Motus Nova began a decade ago pioneering a robotics device using Artificial Intelligence (AI) to accelerate recovery from neurological injuries such as strokes. Named one of the 10 Most Innovative Companies in Georgia by the Technology Association of Georgia in 2019, Motus Nova is now transitioning from years of success in the clinical setting—where its system has helped thousands of stroke survivors regain their independence—to bring its benefits to stroke survivors continuing their rehabilitation at home.
Clinical studies show that neuroplasticity begins after approximately many 10’s to 100’s of hours of active guided rehab. The healing process can take months or years, and sometimes the individuals might never fully recover. Yet the typical regimen for stroke survivors is only two to three hours of outpatient therapy per week for a period of three to four months.
“These constraints were instituted by the Centers for Medicare & Medicaid Services (CMS) in determining Medicare reimbursement without a full understanding of the appropriate dosing required for stroke recovery, and many private insurers have adopted the policy, as well,” said David Wu, Motus Nova’s CEO. Motus Nova plans to offer a more practical model. “By making the system available for home use at a reasonable weekly rate as long as the patient needs it, the individual can perform therapy anytime,” Wu said. “A higher dosage of therapy can be achieved without the inconvenience of scheduling appointments with therapists or traveling to and from a clinic, and without the high cost of going to an outpatient center every time the individual wants to do therapy. We are looking forward to offering this new model. More details about pricing and ordering will be available as we approach our projected launch date this summer.”
Praise from clinicians, users
In his 2017 book, “Best Care Everywhere,” David Shulkin, MD, former Secretary of the U.S. Department of Veterans Affairs (VA), wrote that the Motus Nova Hand and Foot Mentors represent “some of the best and brightest ideas that have been developed … [and] are currently being scaled for national implementation, so that Veterans across the country have access to the innovative and effective care they deserve.” In addition, VA studies estimate about 50% institutional costs savings for hospitals using the Motus Nova system.
Dr. Daniel Schlatterer, MD, is an orthopedic surgeon and a stroke survivor who has used the Motus Nova system with good results. “I’m an orthopedic surgeon in a trauma center in downtown Atlanta, and a little over two years ago at the age of 48 had a stroke. I’ve tried just about everything and I can tell you that this has helped and made a difference. I’ve seen improvements in my wrist motion since I’ve started this. I’m making steady progress in improvement.”
AI for a personalized medicine approach
While the system gathers data about individual performance, AI tailors the regimen to maximize user gains, discover new approaches, minimize side effects and help the stroke survivor realize his or her full potential more quickly. “By optimizing factors such as frequency, intensity, difficulty, encouragement and motivation, the AI system builds a personalized medicine plan uniquely tailored to each individual user of the system,” said Dr. Housley. “Our system is durable, too, proven in clinical trials to deliver an engaging physical therapy experience over thousands of repetitions. We look forward to making it available on a much wider scale in the coming months.”